Acelyrin tops its $250M crossover with new $300M cash raise from blue-chip syndicate
Shao-Lee Lin and her LA-based team at Acelyrin are back — and bringing its largest financing haul yet.
The biotech reported a $300 million Series C round Tuesday morning, sending the company over the half-billion dollar mark in venture financing since it was founded more than two years ago. The goal, according to the biotech, is to push forward Phase III development of so-far sole candidate izokibep — in psoriatic arthritis and axial spondyloarthritis — through BLA submission.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 170,400+ biopharma pros reading Endpoints daily — and it's free.